Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,866 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 823
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +18.8%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (418)

clinicaltrialsPublishedShowing 2,451–2,500 of 2,866 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01163539	Cyberknife Radiosurgery and Quality of Life	terminated	—	15	Stanford UniversityOTHER	1	Jul 1, 2016	clinicaltrials
NCT02815410	Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients	unknown	Phase 2	73	Seoul National University HospitalOTHER	0	Jun 28, 2016	clinicaltrials
NCT02779101